Can Cemiplimab Become a Life-Changer in Xeroderma Pigmentosum?

Maria Boziou; Dimitrios Dionyssiou; Dimitrios Dionyssopoulos; Elizabeth Lazaridou; Aimilios Lallas; Zoe Apalla

doi:10.5826/dpc.1303a160

Can Cemiplimab Become a Life-Changer in Xeroderma Pigmentosum?

Authors

Maria Boziou Second Dermatology Department, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece
Dimitrios Dionyssiou Department of Plastic Surgery, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece
Dimitrios Dionyssopoulos Department of Medical Oncology, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece
Elizabeth Lazaridou Second Dermatology Department, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece
Aimilios Lallas First Dermatology Department, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece
Zoe Apalla First Department of Dermatology, Aristotle University Thessaloniki, Greece

Keywords:

immune checkpoint inhibitors, cemiplimab, xeroderma pigmentosum, squamous cell carcinoma, melanoma

References

Rubatto M, Merli M, Avallone G, et al. Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review. Oncotarget. 2021;12(11):1116-1121. DOI: 10.18632/oncotarget.27966. PMID: 34084285. PMCID: PMC8169062.

Ameri AH, Mooradian MJ, Emerick KS, et al. Immunotherapeutic strategies for cutaneous squamous cell carcinoma prevention in xeroderma pigmentosum. Br J Dermatol. 2019;181(5):1095-1097. DOI: 10.1111/bjd.18144. PMID: 31102460.

Hauschild A, Eichstaedt J, Möbus L, et al. Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab. Eur J Cancer. 2017;77:84–87. DOI: 10.1016/j.ejca.2017.02.026. PMID: 28365530.

Deinlein T, Lax SF, Schwarz T, Giuffrida R, Schmid- Zalaudek K, Zalaudek I. Rapid response of metastatic cutaneous squamous cell carcinoma to pembrolizumab in a patient with xeroderma pigmentosum: Case report and review of the literature. Eur J Cancer. 2017;83:99–102. DOI: 10.1016/j.ejca.2017.06.022. PMID: 28734147.

Chambon F, Osdoit S, Bagny K, Moro A, Nguyen J, Réguerre Y. Dramatic response to nivolumab in xeroderma pigmentosum skin tumor. Pediatr Blood Cancer. 2018;65(2). DOI: 10.1002/pbc.26837. PMID: 28988442.

Salomon G, Maza A, Boulinguez S, et al. Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosum. Br J Dermatol. 2018;178(5):1199-1203. DOI: 10.1111/bjd.16270. PMID: 29274233.

Steineck A, Krumm N, Sarthy JF, et al. Response to Pembrolizumab in a Patient With Xeroderma Pigmentosum and Advanced Squamous Cell Carcinoma. JCO Precis Oncol. 2019;3:PO.19.00028. DOI: 10.1200/PO.19.00028. PMID: 32923855. PMCID: PMC7446378.

Momen S, Fassihi H, Davies HR, et al. Dramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: whole-genome sequencing aids treatment decision in end-stage disease. Cold Spring Harb Mol Case Stud. 2019;5(5):a004408. DOI: 10.1101/mcs.a004408. PMID: 31645345. PMCID: PMC6824248.